Dong-A ST Co., Ltd. 170900
KRX · South Korea · Health Technology
KRW 34,950.000.00 (0.00%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel (DA-1241), its novel, orally available G-protein-coupled receptor 119 (GPR119) agonist. This currently includes 48 granted and pending patents across three patent families in the U.S., Europe, Japan, China and other countries, providing protection into 2035, unless extended further.
The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced toxicity, targeting diverse cancer types. Collaborations and innovations, such as nanobody-based and engineered linker technologies, further expand potential.Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders. This currently includes 39 granted and pending patents in the U.S. and internationall
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.